image description

Incubator Facility. Incubator Graduates

Incubator Graduates:

Abeona Therapeutics

Learn more about Abeona Therapeutics

Abeona is developing novel gene therapies for children with rare genetic diseases. Our initial programs utilize technology exclusively licensed from Nationwide Children’s Hospital for the treatment of the deadly childhood genetic diseases Mucopolysaccharidosis (MPS) IIIA and IIIB. Also known as Sanfilippo Syndromes type A and type B, MPS III is a progressive neuromuscular disease with profound CNS involvement.1-3 MPS III is a devastating lysosomal storage disease (LSD), caused by a single gene defect consisting of autosomal recessive defects in a lysosomal enzyme essential for the stepwise breakdown of a class of biologically important glycosaminoglycan (GAG), heparan sulfates.4-6 This results in in dramatic loss of intellectual ability due to improper cell function within the central nervous system (CNS), which results in cognitive decline, motor dysfunction, and eventual death.

Our two lead products, ABX-A and ABX-B, are viral vector based gene transfer drugs that can deliver the functioning version of the Sanfilippo genes to the CNS with the aim of reversing the effects of the genetic errors that cause the disease. After a single dose in Sanfilippo animals, ABX-A and ABX-B induced cells in the CNS and peripheral organs to produce the missing enzymes and help repair damage caused to the cells.

Safety studies conducted in large animal models have demonstrated that delivery of ABX-A and ABX-B are well tolerated with minimal side effects. Importantly, efficacy studies in animals with Sanfilippo syndrome have demonstrated functional benefits that remain for months after treatment. A single dose of ABX-A or ABX-B significantly restored normal cell and organ function, corrected cognitive defects that remained months after drug administration, increased neuromuscular control and increased the lifespan of animals with SF over 100% one year after treatment compared to untreated control animals. These results are consistent with studies from several laboratories suggesting ABX-A and ABX-B treatment could potentially benefit patients with for Sanfilippo Syndrome Type A and B, respectively. Development of a cost-effective treatment that can be administered as a single injection with the potential to significantly improve the quality of life of patients with Sanfilippo may have a major impact on an incipient $400M market. Activities leading to IND applications for both therapies are fully funded by disease foundations and NIH grants.

The Company closed on initial funding of $750,000 in November 2013 and currently seeks up to $5M to develop both ABX-A and ABX-B through Phase I/II clinical trials for treatment of Sanfilippo Syndromes A and B. Both ABX-A and ABX-B have received Orphan Drug Designation from the USA FDA.

Cleveland HeartLab, LLC

Learn more about Cleveland HeartLab, LLC

Cleveland HeartLab, LLC is a Cleveland-based specialty clinical laboratory and disease management company focused on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. The company has developed a profile of tests focused on managing and reducing inflammation, a root cause of heart disease.

Explorys Inc.

Learn more about Explorys Inc.

Explorys formed a partnership with Cleveland Clinic, Explorys addresses the national imperative to leverage electronic health records (EHR) for the improvement of medicine. Our networked platform enables the discovery of critical correlations, trends, and outcomes across millions of patients, clinical records, and diverse environments — providing unique insight to enable providers and life sciences organization to deliver safer, more efficient and more effective healthcare. This capability creates new opportunities for healthcare providers and life sciences organizations to partner, collaborate, and identify breakthroughs in safety, innovation, and efficiency in the delivery of care.

Image IQ

Learn more about Image IQ

ImageIQ provides expertise in the incorporation of advanced image acquisition, processing, analysis and visualization into the research and development of biotechnologies. Serving the research, medical device, pharmaceutical and legal markets, ImageIQ has helped improve the effectiveness of R&D, product development, regulatory approval and product liability litigation through the use of their customizable software platforms and unique imaging-based approach to solving biomedical problems. ImageIQ also works with scientists and clinicians throughout the world to develop novel medical technologies ranging preoperative surgical planning software to image-based diagnostics for detecting the early onset of hypertension and diabetes. For more information, please contact Tim Kulbago:

Juventas Therapeutics

Learn more about Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways. The company’s lead product encodes stromal cell-derived factor-1 (SDF-1) which has been shown to significantly increase end-organ function following tissue injury.


Learn more about PediaCath

PediaWorks and Medikit agreed that children should have access to the same medical advancements as adults, but very few pediatric products were actually reaching the market.  So in 2009 they partnered to form PediaCath, the first and only organization to develop catheters just for children.  PediaCath leverages Medikit’s experienced team of R&D engineers and rapid prototyping facilities, and PediaWorks access to a broad network of pediatric clinical advisors and research partners.  PediaCath’s initial focus is on catheters used by cardiologists. For more information contact Tim Moran via

Global Cardiovascular Innovation Center